Multiple Sclerosis, Primary Progressive Clinical Trial
Official title:
Follow-up Study of the Effectiveness of Virtual Reality Therapy in MS Patients
Different therapies can improve clinical and motor symptoms of multiple sclerosis (MS) similarly, but studies comparing the effects of different exercise therapies on clinical and motor outcomes are scant. We compared the effects of exergaming (EXE), balance (BAL), cycling (CYC), proprioceptive neuromuscular facilitation (PNF), and a standard care wait-listed control group (CON) on clinical and motor symptoms and quality of life (QoL) in people with MS (PwMS). Methods: PwMS (n = 68, 90% female; age, 47.0 yr; Expanded Disability Status Scale score 5-6) were randomized into five groups. Before and after the interventions (five times a week for 5 wk), PwMS were tested for MS-related clinical and motor symptoms (Multiple Sclerosis Impact Scale-29 (MSIS-29), primary outcome), QoL (EuroQol Five Dimensions Questionnaire), symptoms of depression, gait and balance ability (Tinetti Assessment Tool), static and dynamic balance and fall risk (Berg Balance Scale), walking capacity (6-min walk test), and standing posturography on a force platform. Patients were followed up for 2 years after 5 weeks of intensive care. Tests are performed every six months.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03455582 -
Cognition Evolution and MRI Markers in PPMS Patients on 2 Years
|
N/A | |
| Active, not recruiting |
NCT04544449 -
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
|
Phase 3 | |
| Recruiting |
NCT04918225 -
Motor Asymmetry in Progressive Multiple Sclerosis Patients
|
||
| Completed |
NCT02913157 -
Hydroxychloroquine in Primary Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT01982942 -
Safety, Tolerability and Activity Study of Ibudilast in Subjects With Progressive Multiple Sclerosis
|
Phase 2 | |
| Recruiting |
NCT05204459 -
MS-ResearchBiomarkerS
|
||
| Recruiting |
NCT05663853 -
An Observational Biomarker Study in Multiple Sclerosis (MS) Patients
|
||
| Completed |
NCT01194570 -
A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT02305264 -
Imaging of Intracerebral Inflammation in MS
|
N/A | |
| Completed |
NCT03679468 -
Improving Cognition in People With Progressive Multiple Sclerosis Using Aerobic Exercise and Cognitive Rehabilitation
|
N/A | |
| Recruiting |
NCT05496881 -
Exercise Effects in Multiple Sclerosis
|
N/A | |
| Completed |
NCT02506751 -
Open-label Study of Liothyronine in MS
|
Phase 1 | |
| Temporarily not available |
NCT02606929 -
Use of Well Known Drugs for New Destination - MS Improvement (MSNT)
|
Phase 0 | |
| Completed |
NCT03424538 -
The Effect of Neurorehabilitation Therapy on Postural Control, Mobility and Quality of Life in Multiple Sclerosis Patients
|
N/A | |
| Completed |
NCT04545372 -
Aerobic Exercises for Multiple Sclerosis
|
N/A | |
| Recruiting |
NCT05122559 -
Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis
|
Phase 2 | |
| Completed |
NCT02988401 -
Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis
|
Phase 1/Phase 2 | |
| Completed |
NCT02632591 -
Use on Human Beings of Mix of Known Drugs for New Destination - MS Treatment
|
Phase 1 | |
| Completed |
NCT01917019 -
A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis
|
Phase 3 | |
| Completed |
NCT01433497 -
Efficacy and Safety of Masitinib in the Treatment of Progressive Multiple Sclerosis
|
Phase 3 |